TITLE

Toxic and drug-induced myopathies

PUB. DATE
August 2009
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Aug2009, Vol. 80 Issue 8, p832
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Drugs used for therapeutic interventions either alone or in combination may sometimes cause unexpected toxicity to the muscles, resulting in a varying degree of symptomatology, from mild discomfort and inconvenience to permanent damage and disability. The clinician should suspect a toxic myopathy when a patient without a pre-existing muscle disease develops myalgia, fatigue, weakness or myoglobinuria, temporally connected to the administration of a drug or exposure to a myotoxic substance. This review provides an update on the drugs with well-documented myocytoxicity and cautions the clinicians to be alert for the potential toxicity of newly marketed drugs; highlights the clinical features and pathomechanisms of the induced muscle disease; and offers guidance on how best to treat and distinguish toxic myopathies from other acquired or hereditary muscle disorders. Practical issues regarding the diagnosis and management of statin-induced myopathies are emphasized. Myotoxicity resulting from direct insertion of transgenes to the muscle, an exciting new tool currently tested for treatment of muscular dystrophies, is also discussed.
ACCESSION #
43423685

 

Related Articles

  • Inclusion body myositis. Badrising, Umesh A.; Maat-Schieman, Marion L. C.; van Houwelingen, Johannes C.; van Doorn, Pieter A.; van Duinen, Sjoerd G.; van Engelen, Baziel G. M.; Faber, Carin G.; Hoogendijk, Jessica E.; de Jager, Aeiko E.; Koehler, Peter J.; de Visser, Marianne; Verschuuren, Jan J. G. M.; Wintzen, Axel R. // Journal of Neurology;Dec2005, Vol. 252 Issue 12, p1448 

    The clinical features of inclusion body myositis (IBM) were of minor importance in the design of consensus diagnostic criteria, mainly because of controversial views on the specificity of signs and symptoms, although some authors reported "typical" signs. To re–assess the clinical...

  • Congenital myopathies: Clinical and immunohistochemical study. Thaha, Fazil; Gayathri, N.; Nalini, A. // Neurology India;Nov2011, Vol. 59 Issue 6, p879 

    Congenital myopathies (CMs), a group of relatively non-progressive disorders presents with weakness and hypotonia of varying severity, morphologically recognized by specific structural abnormalities within the myofiber. This report presents the clinical and Histopathological features of 40...

  • Muscle stem cells can act as antigen-presenting cells: implication for gene therapy. Cao, B.; Bruder, J.; Kovesdi, I.; Huard, J. // Gene Therapy;Sep2004, Vol. 11 Issue 17, p1321 

    Research has shown that the use of a muscle-specific promoter can reduce immune response and improve gene transfer to muscle fibers. We investigated the efficiency of direct and ex vivo gene transfer to the skeletal muscles of 6- to 8-week-old mdx mice by using two adenoviral vectors: adenovirus...

  • Assessment of an electronic goniometer designed to measure eqinus contracture. Assal, Mathieu // Journal of Rehabilitation Research & Development;May/Jun2003, Vol. 40 Issue 3, pxii 

    Presents an abstract of the study 'Assessment of an Electronic Goniometer Designed to Measure Equinus Contracture,' by Mathieu Assal, Jane B. Shofer, Eric Rohr, Robert Price, Joseph Czerniecki and Bruce J. Sangeorzan.

  • HALLMARKS OF FIBROMYALGIA.  // Massage Magazine;Nov2006, Issue 126, p47 

    The article presents the distinctive characteristics or attribute of fibromyalgia. Pain is most often bilateral and is present in all four quadrants of the body. People with fibromyalgia often wake up tired even though they seem to get plenty of sleep. Individuals with fibromyalgia are often...

  • Mutations in embryonic myosin heavy chain (MYH3) cause Freeman-Sheldon syndrome and Sheldon-Hall syndrome. Toydemir, Reha M.; Rutherford, Ann; Whitby, Frank G.; Jorde, Lynn B.; Carey, John C.; Bamshad, Michael J. // Nature Genetics;May2006, Vol. 38 Issue 5, p561 

    The genetic basis of most conditions characterized by congenital contractures is largely unknown. Here we show that mutations in the embryonic myosin heavy chain (MYH3) gene cause Freeman-Sheldon syndrome (FSS), one of the most severe multiple congenital contracture (that is, arthrogryposis)...

  • Mitochondrial Myopathy, Sideroblastic Anemia, and Lactic Acidosis: An Autosomal Recessive Syndrome in Persian Jews Caused by a Mutation in the PUS1 Gene. Zeharia, Avraham; Fischel-Ghodsian, Nathan; Casas, Kari; Bykhovskaya, Yelena; Tamari, Hana; Lev, Dorit; Mimouni, Marc; Lerman-Sagie, Tally // Journal of Child Neurology;May2005, Vol. 20 Issue 5, p449 

    We report the seventh case of autosomal recessive inherited mitochondrial myopathy, lactic acidosis, and sideroblastic anemia. The patient, a product of consanguineous Persian Jews, had the association of mental retardation, dysmorphic features, lactic acidosis, myopathy, and sideroblastic...

  • Bilateral lateral rectus recession considering the tendon width in intermittent exotropia. Lee, H.; Kim, S.-H. // Eye;Sep2009, Vol. 23 Issue 9, p1808 

    PurposeThe tendon width of the lateral rectus muscle can be a useful indicator of the effect of unilateral lateral rectus recession in intermittent exotropia.1 The aim of this study was to determine whether the tendon width of lateral rectus would be useful for predicting the effect of bilateral...

  • Freeman-Sheldon syndrome: A dental perspective. Bijumon; Johns, Dexton A. // Journal of the Indian Society of Pedodontics & Preventive Dentis;Jul-Sep2013, Vol. 31 Issue 3, p184 

    Freeman-Sheldon syndrome is a rare progressive myopathic disorder affecting the face, chest, and limbs. It is characterized by three basic abnormalities: microstomia with pouting lips, camptodactyly with ulnar deviation of the fingers, and talipes equinovarus. Presence of microstomia is always...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics